Results 221 to 230 of about 12,239,410 (293)

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Integrated omics reveal a unique antibacterial mechanism of action for the small molecule HSI#6. [PDF]

Curr Res Microb Sci
Sedky H, Hamed MB, Vermeire K, Schymkowitz J, Karamanou S, Economou A.   +5 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Cardiac Sodium Channel Regulation: A Potential New Therapeutic Target in Cardiomyopathy. [PDF]

Circ Res
Dudley SC.
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Experimental Platform for Screening and Validation of BacNa_v Gene Therapy Candidates. [PDF]

Circ Arrhythm Electrophysiol
Wu T, Nguyen HX, Siu YY, Li Y, Bursac N.
europepmc   +1 more source

Problems in the use of chemical and functional nomenclatures for steroids in human physiology, biology and pharmacology. [PDF]

RSC Adv
Honour JW.
europepmc   +1 more source

Norroa™ as a dsRNA biopesticide for <i>Varroa destructor</i>: insights from New Zealand research on mode of action, field efficacy, non-target effects, and social acceptance. [PDF]

Front Insect Sci
Lester PJ, Bulgarella M, Manley B, Masucci JD, McGruddy RA, Merk J, Narva K, Palmer S, Mercier OR, Smeele ZE.   +9 more
europepmc   +1 more source

DNA-intercalating antiphage molecules trigger abortive infection through mutual destruction and synergize with bacterial immunity. [PDF]

Proc Natl Acad Sci U S A
Ernst L, Gätgens C, Rackow B, Pozhydaieva N, Gaaloul E, Krüger A, Seiffarth J, Bund M, Joisten-Rosenthal V, Kohlheyer D, Usadel B, Harms A, Höfer K, Frunzke J.   +13 more
europepmc   +1 more source

Analytical and Clinical Validation of Action PharmaKitDx: A Comprehensive NGS Panel for the Identification of Pharmacogenetic Variants in Diverse Populations. [PDF]

Pharmaceuticals (Basel)
Ramudo-Cela L, Izquierdo-García M, Dolores-Sequedo M, Cubells-Perez V, Bernal S, Riera P, Lasa A, Torres-Juan L, Asensio VJ, Martínez-López I, Obrador de Hevia A, Morín M, Moreno-Pelayo MÁ, Carmona-Antoñanzas G, Pelayo JP.   +14 more
europepmc   +1 more source